Skip to main content

Animations

MJFF Publications

5741 - 5750 of 8785 Results
Title
Year
  • Year
  • 2021
  • 2021
  • 2022
  • 2022
  • 2022
  • 2022
  • 2021
  • 2022
  • 2022
  • 2022
  • Summary Details
    RESTRICTED
    Title: A conversation with Judith Campisi: Leader in the field of aging research
    Journal Name: Ageing Research Reviews
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.arr.2021.101366
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Data imputation and compression for Parkinson's disease clinical questionnaires
    Journal Name: Artificial Intelligence in Medicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.artmed.2021.102051
    Citation Count: 23
  • Summary Details
    OPEN
    Title: Subtle anomaly detection: Application to brain MRI analysis of de novo Parkinsonian patients
    Journal Name: Artificial Intelligence in Medicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.artmed.2022.102251
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson’s disease and cognition
    Journal Name: Brain, Behavior, and Immunity
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.bbi.2022.01.005
    Citation Count: 43
  • Summary Details
    OPEN
    Title: The ADORA1 mutation linked to early-onset Parkinson’s disease alters adenosine A1-A2A receptor heteromer formation and function
    Journal Name: Biomedicine & Pharmacotherapy
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.biopha.2022.113896
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson’s disease
    Journal Name: Biomedicine & Pharmacotherapy
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.biopha.2022.113908
    Citation Count: 6
  • Summary Details
    OPEN
    Title: The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44
    Journal Name: Molecular Genetics and Metabolism
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.ymgme.2021.03.012
    Citation Count: 3
  • Summary Details
    RESTRICTED
    Title: Inconsistency and incongruence: the two diagnostic pillars of functional movement disorder
    Journal Name: The Lancet
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s0140-6736(22)01184-9
    Citation Count: 7
  • Summary Details
    RESTRICTED
    Title: Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synuclein
    Journal Name: Nuclear Medicine and Biology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00207-4
    Citation Count: 0
  • Summary Details
    RESTRICTED
    Title: Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursors
    Journal Name: Nuclear Medicine and Biology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00209-8
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.